儿童与成人重症哮喘核心结局指标集的制定(COMSA)
COMSA工作组通过多利益相关方共识流程,为儿童和成人重症哮喘制定了核心结局指标集(COM sets)。两套指标集均包含FEV1 z评分、年重度急性发作频率和维持口服糖皮质激素使用;儿童集另含PAQLQ和ACT/C-ACT,成人集另含SAQ和ACQ-6。预期这些指标集将指导未来临床试验方法学,增强生物制剂疗效与效果的可比性。
要点
- 儿童与成人重症哮喘COM集均含FEV1 z评分、年重度急性发作频率和维持口服激素使用。
- 儿童COM集额外纳入PAQLQ和ACT或C-ACT。
- 成人COM集额外纳入SAQ和ACQ-6(症状与急救药物使用分开报告)。
核心结论
- COMSA制定了儿童和成人重症哮喘两套核心结局指标集,以促进生物制剂研究数据的合成与评价。
研究设计与样本
- COMSA采用多利益相关方共识流程,参与者包括重症哮喘患者、成人及儿科临床医生、制药代表和欧洲卫生监管机构。
- 证据基础包括对所选结局指标开发、效度和信度的系统综述、叙述性综述以及泛欧洲调查。
- 使用改良GRADE证据到决策框架进行讨论,并采用预先定义的共识标准进行匿名投票。
主要发现
- 儿童和成人COM集均包含FEV1 z评分、年重度急性发作频率和维持口服糖皮质激素使用。
- 儿童COM集还包括儿童哮喘生活质量问卷(PAQLQ)和哮喘控制测试(ACT)或儿童哮喘控制测试(C-ACT)。
- 成人COM集还包括重症哮喘问卷(SAQ)和哮喘控制问卷-6(ACQ-6),症状与急救药物使用分开报告。
关键数值与推荐
- 儿童COM集:FEV1 z评分、年重度急性发作频率、维持口服糖皮质激素使用、PAQLQ、ACT或C-ACT。
- 成人COM集:FEV1 z评分、年重度急性发作频率、维持口服糖皮质激素使用、SAQ、ACQ-6(症状和急救药物使用分开报告)。
临床怎么用
- 未来儿童和成人重症哮喘临床试验及生物制剂疗效评价应采用COMSA核心结局指标集。
- COMSA将用于指导重症哮喘生物制剂治疗无应答和应答的定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effectiveness studies with biological therapies for asthma lack standardised outcome measures. The COMSA (Core Outcome Measures sets for paediatric and adult Severe Asthma) Working Group sought to develop Core Outcome Measures (COM) sets to facilitate better synthesis of data and appraisal of biologics in paediatric and adult asthma clinical studies. METHODS: COMSA utilised a multi-stakeholder consensus process among patients with severe asthma, adult and paediatric clinicians, pharmaceutical representatives, and health regulators from across Europe. Evidence included a systematic review of development, validity and reliability of selected outcome measures plus a narrative review and a pan-European survey to better understand patients' and carers' views about outcome measures. It was discussed using a modified GRADE (Grading of Recommendations Assessment, Development and Evaluation) Evidence to Decision framework. Anonymous voting was conducted using predefined consensus criteria. RESULTS: Both adult and paediatric COM sets include forced expiratory volume in 1 s (FEV1) as z-scores, annual frequency of severe exacerbations and maintenance oral corticosteroid use. Additionally, the paediatric COM set includes the Paediatric Asthma Quality of Life Questionnaire and Asthma Control Test or Childhood Asthma Control Test, while the adult COM set includes the Severe Asthma Questionnaire and Asthma Control Questionnaire-6 (symptoms and rescue medication use reported separately). CONCLUSIONS: This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma.
引用
- Khaleva E, Rattu A, Brightling C, et al. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). Eur Respir J. 2023. PMID: 36229046. doi:10.1183/13993003.00606-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。